A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations
Condition: Metastatic Colorectal Cancer
MeSH terms: Colorectal Neoplasms
Intervention: Selinexor; Pembrolizumab; Trifluridine; Tipiracil
Intervention description: Participants will receive selinexor oral tablets.; Participants will receive pembrolizumab intravenously.; Participants will receive trifluridine oral tablets as SOC.; Participants will receive tipiracil oral tablets as SOC.
Intervention MeSH terms: Trifluridine; Pembrolizumab
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Enrollment: 13.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      The purpose of this study is to evaluate the efficacy and safety of selinexor alone or with
      pembrolizumab in participants with advanced or metastatic colorectal cancer (CRC).
      Approximately 78 participants with advanced or metastatic CRC will be enrolled, and
      randomized (1:1:1) into three arms A (selinexor only), B (selinexor and pembrolizumab), and C
      (standard of care [Combination of trifluridine and tipiracil]). Randomization will be based
      on stratification factors: Eastern Cooperative Oncology Group (ECOG) performance status 0 or
      1 versus 2. The end of treatment (EoT) visit will occur less than or equal to (<=30) days
      post-treatment discontinuation. A survival follow-up visit will be performed every 3 months
      from EoT and will continue for 12 months.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Participants have histologically proven diagnosis of unresectable metastatic
             colorectal cancer with a known rat sarcoma (RAS) mutation.

          -  Participants have measurable disease according to RECIST 1.1 criteria.

          -  Have received 2-3 prior lines of systemic anticancer treatment (adjuvant or
             neoadjuvant therapy is not counted as one line of systemic therapy).

          -  Participants with stable previously treated brain metastases are allowed.

          -  ECOG performance status of 0-2 at the time of screening.

          -  Age ≥ 18 years at the time of signing informed consent

          -  Life expectancy of at least 3 months.

          -  Female participants of childbearing potential must agree to use dual methods of
             contraception and have a negative serum pregnancy test at screening, and male
             participants must use an effective barrier method of contraception if sexually active
             throughout the study and for 4 months after the last dose of selinexor or
             pembrolizumab or 6 months after trifluridine and tipiracil.

          -  Written informed consent signed in accordance with federal, local, and institutional
             guidelines.

        Exclusion Criteria:

          -  Prior treatment with a selective inhibitor of nuclear export (SINE) compound or
             selinexor.

          -  Prior treatment with immune checkpoint inhibitors.

          -  Participants with microsatellite instability high (MSI-H) or deficient mismatch repair
             (dMMR).

          -  Known allergy to any of study drugs (selinexor, pembrolizumab, and trifluridine and
             tipiracil) or the excipient of pembrolizumab.

          -  Significant cardiovascular impairment, defined as:

               -  Left ventricular ejection fraction ≤ 40 percent (%)

               -  Active congestive heart failure (New York Heart Association [NYHA]) Class ≥ 3

               -  Unstable angina or myocardial infarction within 3 months of enrollment

               -  Serious and potentially life-threatening arrhythmia

          -  Impaired hematopoietic function (any of the following would result in exclusion):

               -  Absolute neutrophil count (ANC) less than (<) 1500/cubic millimeter (mm^3)

               -  Platelet count < 100,000/ mm^3

               -  Hemoglobin (Hb) < 10 gram per deciliter (g/dL)

          -  Significant renal impairment, defined as: calculated creatinine clearance (CrCl) of <
             30 milliliter per minute (mL/min) using the formula of Cockcroft and Gault.

          -  Impaired hepatic function defined as: total bilirubin greater than (>) 1.5 × upper
             limit of normal (ULN) and aspartate transaminase (AST) > 2.5 x ULN, AST > 2.5 x ULN;
             for Arm B, unless bilirubin elevation is related to Gilbert's Syndrome for which
             bilirubin must be ≤ 4 x ULN.

          -  Participants with a diagnosis of immunodeficiency or are receiving systemic steroid
             therapy (>10 mg/day of prednisone or equivalent) or any other form of
             immunosuppressive therapy. Participants with active autoimmune disease requiring
             systemic treatment during the past 2 years.

               -  Participants with controlled type I and type II diabetes mellitus, and
                  endocrinopathies such as hypothyroidism on stable hormone replacement, skin
                  disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic
                  treatment, or conditions not expected to recur in the absence of an external
                  trigger are allowed.

        Note: The Investigator needs to evaluate the participants medical history to confirm that
        they are eligible to receive the combination with pembrolizumab per these criteria.

          -  Insufficient time since or not recovered from procedures or anti-cancer therapy,
             defined as:

               -  Not recovered from major surgery ≤ 21 days prior to Day 1 dosing. Minor
                  procedures, such as biopsies, dental work, or placement of a port or IV line for
                  infusion are permitted.

               -  Have ongoing clinically significant anti-cancer therapy-related toxicities Common
                  Terminology Criteria for Adverse Events (CTCAE) Grade > 1. In specific cases,
                  participants whose toxicity has stabilized or with Grade 2 non-hematologic
                  toxicities can be allowed following documented approval by the Sponsor's Medical
                  Monitor.

               -  Had last dose of previous anti-cancer therapy ≤14 days prior to Day 1 dosing.

               -  Palliative radiotherapy > 14 days prior to the study is allowed.

               -  Received investigational drugs in other clinical trials within 28 days, or 5
                  half-lives of the investigational drug (whichever is shorter), prior to Cycle 1
                  Day 1 (C1D1).

               -  Live-attenuated vaccine against an infectious disease (e.g., nasal spray
                  influenza vaccine) ≤ 14 days prior to the intended C1D1.

          -  Female participants who are pregnant or lactating.

          -  Active, ongoing or uncontrolled active infection requiring parenteral antibiotics,
             antivirals, antifungals within 1 week of Screening.

          -  Participants with autoimmune disease, a medical condition that requires systemic
             corticosteroids or other immunosuppressive medication; or a history of interstitial
             lung disease.

          -  Any gastrointestinal dysfunctions that could interfere with the absorption of
             selinexor (e.g. bowel obstruction, inability to swallow tablets, malabsorption
             syndrome, unresolved nausea, vomiting, diarrhea CTCAE > grade 1).

          -  In the opinion of the investigator, participants who are below their ideal body weight
             and would be unduly impacted by changes in their weight.

          -  Serious psychiatric or medical conditions that could interfere with participation in
             the study or in the opinion of the Investigator would make study involvement
             unreasonably hazardous.

          -  Concurrent therapy with approved or investigational anticancer therapeutic including
             topical therapies.